Psychometric Assessment:

Cross-sectional and longitudinal cognitive characteristics of all subjects are shown in Table 2. We did not find any statistically significant differences between OSA indices and cognition across healthy and OSA groups at baseline or longitudinally. To assess the relationship between longitudinal changes in CSF $A\beta_{42}$ and cognitive performance, we performed Pearson correlation analyses comparing annual rate of change of CSF Aβ42 and annual change in cognitive z-scores. No statistically significant correlations were found: Logic 2 (r=-.12, n.s.), AF (r=.15, n.s.), VF (r=.09, n.s.), BNT (r=.006, n.s.), DSST (r=.16, n.s.), TMT-A (r=.001, n.s.) and TMT-B (r=-.08, n.s.).

CSF and PET Assessment:

From the 208 participants, 179 subjects performed a lumbar puncture (LP) at baseline. A second LP was obtained at follow-up in 104 subjects 2.42±0.88 years later. 86 subjects performed PiB scans at baseline. A second PiB scan evaluation was obtained at follow-up in 34 subjects 2.50±0.39 years later. 57 participants performed both the LP and the PET scans at baseline. 25 participants performed the LP and PET scans at both baseline and follow-up (Figure 5). We will refer to participants with both baseline and follow-up biomarker data available as "*completers",* whereas subjects with only baseline biomarkers data will be referred to as "*non-completers"*. There were no differences between *completers* and *non-completers,* in terms of (age [t=-.27, n.s.], sex [X^2=.002, n.s.], BMI [t=.40, n.s.], MMSE [t=.00, n.s.], years of education [t=.17, n.s.], ApoE4 status [X^2=.93, n.s.], TST [t=1.18, n.s.], AHIall [t=.82, n.s.] or AHI4% [t=.88, n.s.]). Summary statistics of baseline, and annual changes of AD biomarkers are shown in Table 3. No significant associations were observed between annual changes in CSF $A\beta_{42}$ and age ($F_{1,93}$=2.23, p=.13, β=-1.68, 95% Confidence Interval [CI]= -.39 to .55, p=.13), sex ($F_{1,93}$=.64, p=.42, β=13.64, 95% CI = -20.17 to 47.47, p=.42), BMI ($F_{1,93}$=.16, p=.69, β=-.61, 95% CI=-3.67 to 2.44, p=.69) or ApoE4 ($F_{1,93}$=.42, p=.51, β=-11.35, 95% CI= -46.03 to 23.32, p=.51). At cross-section and longitudinally, we did not find any significant differences among the 3 OSA severity groups for CSF P-Tau or T-Tau. Similarly, no cross-sectional or longitudinal effects were found for CSF $A\beta_{42}$ across OSA severity groups using univariate analysis. No significant correlation between CSF $A\beta_{42}$ and AHI indices were observed at cross-section.

However, significant correlations were observed between longitudinal change in CSF $A\beta_{42}$ levels and AHIall/AHI4 (rho=-0.24, p<.05, rho=-0.23, p<.05, respectively) and after controlling for age, sex, BMI and ApoE4 (rho=-0.27, p<.05, rho=-0.24, p<.05, respectively). Significant associations were also observed between annual rate of change of CSF $A\beta_{42}$ and AHI indices at baseline using hierarchical linear regression model (shown in table 4), including annual rate of change of CSF $A\beta_{42}$ as dependent and AHI indices (lnAHI4 and lnAHIall) as independent variables, before ($F_{1,92}$=5.41, p<.05, and $F_{1,93}$=4.72, p<.05 respectively) and after accounting for age, sex, BMI and ApoE4 ($F_{1,88}$=4.26, p<.05 and $F_{1,87}$=4.36, p<.05, respectively). The effect of the type of sleep recording device and TST were not significant, thus we excluded them from the final model. Figure 1 shows the relationship between delta change in CSF $A\beta_{42}$ and the AHI indices at baseline. Sensitivity analyses were perfomed excluding 5 subjects whose baseline sleep evaluation was done after their first CSF measurements. Association between lnAHI4, lnAHIall, and annual delta CSF Aβ42 remained unchanged.

Similarly, on univariate analysis no difference in AD_{PiB}-mask was observed between OSA severity groups, and no significant correlation between AD_{PiB}-mask and AHI indices were observed at cross-section. However, correlations were observed between longitudinal change in AD_{PiB}-mask and AHIall or AHI4 (rho=0.374, p<.05, rho=0.302, p=0.09, respectively) after controlling for age, sex, BMI and ApoE4. Using the same hierarchical linear regression model as for CSF $A\beta_{42}$, no statistically significant associations were observed between annual rate of change of AD_{PiB}-mask and AHIs, including annual rate of change of AD_{PiB}-mask as dependent

and AHI indices at baseline as independent variables after accounting for age, sex, BMI and ApoE4. LnAHIall and lnAHI4 were not associated with increases in AD_{PiB}-mask most likely due to the small sample size as there was a trend for lnAHIall ($F_{1,28}$=2.96, p=.09 and $F_{1, 28}$=2.32, n.s. respectively). Figure 2 shows the relationship between delta change in AD_{PiB}-mask and the AHIall index at baseline, both variables were corrected for normal distribution by log transformation.

Further, we analyzed the association between longitudinal change in CSF $A\beta_{42}$ and AD_{PiB}-mask. Using a Pearson correlation, a significant negative correlation between longitudinal change in CSF $A\beta_{42}$ and AD_{PiB}-mask was observed (r=-.44, p<.05). Using an AD_{PiB}-mask SUVR ≥1.4 to define presence of brain amyloid deposition (PiB+),[30-32] a secondary analysis performed only in the initial cross-sectional cases, revealed a significant difference between the slopes of PiB+ and PiB- cases (Figure 3). This was confirmed by the presence of an interaction between PiB status and lnAHI4% ($F_{1,29}$=5.54, p<.05) as well as a positive trend between AHI4% and PiB uptake in PiB+ subjects (rho=0.67, p=.07). Similar findings were observed for AHIall (data not shown). Figure 3 shows the relationships between the AHI4% and PiB SUVR uptake when comparing PiB+ vs. PiB- groups.

DISCUSSION:

The primary objective of this study was to determine if severity of OSA in cognitively normal elderly is associated with CSF and PET AD-biomarkers at cross-section and their longitudinal change across an approximate 2 year period. Our initial finding revealed that OSA was common and affected 53% of our cognitively normal community-dwelling cohort. Second, we demonstrated that baseline OSA severity was associated with two-year longitudinal decreases in CSF $A\beta_{42}$ and a trend towards increases in cortical PiB-PET uptake. Such changes are potentially consistent with increased brain amyloid burden, which were also observed in our cohort (*i.e.,* a negative correlation between longitudinal change in CSF $A\beta_{42}$ and AD_{PiB}-mask), suggesting that OSA may play a role in amyloid deposition in late-life. Moreover, the magnitude of these changes was higher than the one predicted by the presence of the ApoE4 allele alone (Table 4), which to date is considered the most important risk factor for sporadic AD. AHIall, which includes hypopneas associated with oxygen desaturation or arousals, was a better predictor of longitudinal increases in amyloid burden than AHI4%, which includes only hypopneas associated with 4% oxygen desaturation. This raises the possibility that sleep fragmentation is a more critical pathophysiological mechanism by which OSA contributes to AD risk. However, AHIall and AHI4% were highly correlated in our cohort (r=0.91, p<.01) and this study was unable to differentiate the individual effects of sleep fragmentation versus intermittent hypoxia.

Although OSA severity was associated with increases in brain amyloid burden, it was not predictive of cognitive deterioration based on neuropsychological performance, which is in agreement with prior studies.[33;34] This is not completely surprising given that the relationship between amyloid burden and cognition is probably nonlinear and dependent on additional factors such as tau pathology and microvascular changes. Low sensitivity of the neuropsychological tests used may have been another factor. Sensitivity could be increased in the future by employing cognitive tasks that are known to be sleep-dependent.

Current evidence suggests that cognitive decline in AD is associated with decreases in CSF $A\beta_{42}$ and increases in amyloid PET uptake.[35] However, little is known about the temporal course of CSF $A\beta_{42}$ in the preclinical or early stages of the disease, with some recent animal and human studies showing $A\beta_{42}$ elevations prior to $A\beta_{42}$ reductions,[36;37] suggesting an intermediate stage of increased soluble Aβ levels prior to amyloid deposition. Interestingly, we and others have shown that reduced slow wave activity (SWA) at cross-section as well as one night of SWS disruption,

are associated with increases in CSF Aβ levels, potentially as a consequence of increases in neuronal firing and/or decreases in amyloid clearance.[38-41] It remains to be determined how universal a period of elevated CSF $A\beta_{42}$ in humans is observed prior to a decline, but the above mentioned studies suggest that sleep disruption might be associated with elevations of CSF $A\beta_{42}$ which in chronic sleep disorders such as OSA could foster its aggregation and manifest as longitudinal decreases in CSF $A\beta_{42}$ over time such as the one observed in our study. This hypothesis would also explain the absence of significant associations at cross-section. Whether OSA-related sleep fragmentation increases AD-risk through disruption of SWS or other sleep stages is unknown. The ends of apneas are associated with arousals or awakenings that prevent sleep[42] and these are more commonly observed in NREM1-2 and REM sleep. Apneic episodes are less common in SWS, which has been associated with a higher respiratory arousal threshold[43;44] as well as more stable breathing.[45] However, the temporal course of SWA has been shown to be slower in mild OSA,[46] while severe OSA patients show up to a 40% rebound in SWS duration during OSA treatment with CPAP,[47] which suggest that changes in SWS quality may also be involved. However, a recent prospective study reported the association between decreased percentage of REM sleep and increased risk of dementia, implicating also REM sleep as a possible mediator for AD risk.[48] In addition, actigraphy-assessed arousals and circadian rhythm disruption have also been shown to increase the risk of MCI/dementia in the elderly,[49] indicating that the relationship between OSA-related sleep fragmentation and amyloid deposition might not be stage-specific.

Another possible mechanism by which OSA might increase amyloid deposition is through impairment in the CSF-ISF exchange promoted by the glymphatic system[40] resulting in decreased clearance of ISF $A\beta_{42}$. This mechanism was suggested in a recent study of 31 controls and 10 severe OSA middle-age subjects where neuronally derived proteins were decreased in the OSA group when compared to controls.[40] The authors propose that elevations in the intrathoracic and intracranial pressure as well as a sudden pressure reversal at the end of the apnea would impede the glymphatic flow of metabolites from ISF into CSF.[40] Another potential pathway of impairment of CSF-ISF exchange could be cerebral edema secondary to intermittent hypoxia, as proposed recently in a study in which severity of OSA correlated with increased volume and thickness of the left lateral prefrontal cortex as well as increased thickness of the right frontal pole, the right lateral parietal lobules, and the left posterior cingulate cortex.[50] Similar findings were observed as brain volume reductions after six months of treatment with CPAP which also suggests the existence of brain edema in OSA.[51]

Finally, the effects of OSA directly increasing ISF $A\beta_{42}$ burden as suggested by some intermittent hypoxia animals models,[52;53] or indirectly through other intermediate mechanisms such as oxidative stress, sympathetic activation, inflammation, hypercoagulability, endothelial dysfunction or metabolic dysregulation cannot be discarded although it is feasible that these and other consequences of OSA may decline with age[10;54] and might not be as relevant in the elderly as in middle age.

Among participants with initial PiB+ scans at cross-section, Figure 3 suggest that a higher severity of OSA is associated with greater brain Aβ deposition, while no such association is found in participants with PiB- scans, implying that presence or absence of amyloid burden might act as a moderator in these relationships. This would be in agreement with previous studies showing increased amyloid deposition associated with higher AHI indices in MCI patients but not in cognitively normal controls at cross-section.[13] We did not observe this effect in the CSF sample when we compared *amyloid* positive *vs.* negative cases based on the NYU CBH CSF bank $A\beta_{42}$ cut-offs (*i.e.* CSF $A\beta_{42}$ ng/ml <500), so this finding should be interpreted with caution. It may be that the effects of OSA/hypoxia on Aβ aggregation are most pronounced after significant Aβ

accumulation has already occurred, leading to an acceleration of further Aβ deposition in a feed–forward cycle[13] (Figure 4) with OSA-related arousals worsening sleep quality and increasing amyloid deposition. In addition, 33/34 of the subjects that had PiB PET follow-up scans were PiB- at baseline, indicating that the observed longitudinal increases in PiB uptake were not dependent on amyloid status.

Our observations are consistent with our hypothesis that there is an association between severity of OSA-related sleep fragmentation and longitudinal increase in amyloid burden in cognitively normal elderly. This implies that existing therapies for OSA such as CPAP could delay the progression to MCI or dementia in elderly with OSA, as was suggested by our previous epidemiological studies using the ADNI database[11] and a recent cross-sectional study in which OSA patients showed lower CSF $A\beta_{42}$ concentrations, as well as higher T-tau/$A\beta_{42}$ ratio when compared to OSA-CPAP patients.[15]

The high prevalence of mild and moderate to severe OSA in cognitively normal elderly in asymptomatic adults undergoing screening for OSA as part of a protocol on memory and normal aging adds to the importance of these findings. Strengths of our study include that our community residing subjects were not recruited for the study based on sleep complaints, and thus should have been free of selection biases potentially affecting sleep-clinic based cohorts which typically include younger, more frequently male, obese and symptomatic (*e.g.* excessive daytime sleepiness, treatment resistant hypertension, etc.). We also utilized a state-of-the-art method for home-monitoring of OSA, as well as longitudinal standardized CSF and PET biomarkers. Potential weaknesses of the study were the relative short duration and the lack of longitudinal sleep data which did not allow us to test whether preclinical-AD brain lesions increase the risk for OSA, or the lack of a longer clinical assessment to test whether amyloid deposition is followed by cognitive decline to MCI or AD. Another limitation of the study was that not all subjects had a longitudinal follow up, although both *completers* and *non-completers* were not different in terms of sociodemographics, BMI, MMSE, AHIall or AHI4%.

In summary, to our knowledge this study is the first to document that OSA is associated with longitudinal changes in amyloid burden in a sample of cognitively normal elderly. The implication of these findings is that we have identified a contribution of OSA in increasing the amyloid beta burden prior to significant cognitive decline. Our data support testing whether clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances, could be implemented during the early phase in which tissue damage precedes clinical symptoms and neuronal dysfunction, to mitigate the progression of cognitive impairment.

ACKNOWLEDGMENTS:

The authors are indebted to the study subjects for their patience, and for their participation in and contribution to the research. The authors acknowledge contributions to patient recruitment and data collection by Ms. Kimberly Clay, Mr. Michael Yablon, Ms. Christine Grosso, and Ms. Gabriella Petrongolo. They also thank Dr. Pauline McHugh for their assessment of research subjects. This

work was supported by grants from: NIH/NIA/NHLBI R01HL118624, R01HL111724, R21AG049348, R01AG035137, R01AG022374, R01AG13616, R01AG12101 and P30AG008051; Foundation for Research in Sleep Disorders, the American Sleep Medicine Foundation Junior Faculty Award, and the Friedman Brain Institute. Dr. Rosenzweig is supported by the Wellcome Trust [103952/Z/14/Z]. Dr. Zetterberg is supported by the Swedish Research Council (grant no: 2013-2546) and the European Research Council (grant no: 681712). Dr. Nadia Gosselin is supported by a salary award from the *Fonds pour la recherche du Québec – Santé.*

Tables

Table 1: Baseline demographic and sleep characteristics of the subjects

Characteristics	All	Normal	Mild OSA	Moderate-Severe OSA
No. of Participants (%)	208 (100)	97 (46.63)	76 (36.53)	35 (16.82)
Female sex, number (%)	129 (62)	67 (69.1)	44 (57.9)	18 (51.4)

BMI (Kg/m2), median (IQR)	25.79 (22.7,29.87)	24.61 (22.32,28.17)*	26.89 (23.32,29.9)	29.76 (23.49,33.51)*
Age, years, mean ± SD	68.46 ± 7.38	67.56 ± 7.32	68.60 ± 7.19	70.68 ± 7.69
Education, years, median (IQR)	17 (16, 18)	16.5 (16,18)	17 (16,18)	16 (14,19)
Hypertension, number (%)	86 (41.3)	34 (35.1)	32 (42.1)	20 (57.1)
Diabetes, number (%)	12 (5.8)	4 (4.1)	4 (5.3)	4 (11.4)
Cardiovascular disease, number (%)	9 (4.3)	1 (1)	7 (9.2)	1 (2.9)
Thyroid disease, number (%)	34 (16.3)	16 (16.5)	11 (14.5)	7 (20)
APOE4 positive, number (%)	71 (34.1)	34 (35.1)	25 (32.9)	12 (34.3)
AHI4% ,median (IQR)	5 (1.55, 11.40)	1.45 (0.725,3.00)*	7.75 (5.81,10.52)*	25.00 (19.3,37.00)*
AHIall, median (IQR)	17 (10.85, 24.00)	10.40 (6.75,13.65)*	20.05 (17.05, 24.00)*	39.00 (31,57)*
Mean O2 Saturation, median (IQR)	94.19 (93.15, 95.6)	94.57 (93.78,95.6)*	94.9 (92.77,95.71)a	93.47 (92.1,94.5)* a
ESS, median (IQR)	5 (3,8)	4 (3,7)	6 (3.5,8.5)	6 (4,9)
TST,hours, median (IQR)	7 (6.5, 8)	7.48 (6.75,8)	7.00 (6.5,8)	7.50 (6.5,8)

*,a Statistical significant difference between the groups.

Table 2: Cognitive characteristics of NYU cohort at baseline and follow-up evaluations

	All (n=108)	Normal (n=50)	Mild OSA(n=43)	Moderate-Severe OSA (n=15)
MMSE baseline(mean±SD)	29.31 ±0.99	29.40±0.93	29.18±0.98	29.33±1.30
MMSE follow-up	29.36±0.85	29.51±0.718	29.29±0.867	29.00±1.206
CDR baseline	0±0	0±0	0±0	0±0
CDR follow-up	0.010±0.071	0±0	0±0	0.083±0.19
Animal fluency (z-scores)	0.207±0.99	0.24±1.14	0.05±0.81	0.50±0.95
Animal fluency (delta change z-scores)	-0.23±0.87	-0.30±0.98	-0.20±0.85	-0.11±0.54
Vegetable Fluency (z-scores)	-0.042±1.1	-0.023±0.98	-0.14±1.28	0.15±0.96
Vegetable Fluency (delta change z-scores)	-0.14±0.99	-0.39±0.87	0.087±1.08	-0.02±0.98
Boston Naming Test (z-scores)	-0.20±1.03	-0.10±1.06	-0.38±0.98	-0.017±1.07
Boston Naming Test (delta change z-scores)	0.11±0.71	0.24±0.69	0.12±0.71	-0.28±0.69
Logic 1 (z-scores)	0.19±0.96	0.11±1.0	0.24±0.90	0.29±1.05
Logic 1 (delta change z-scores)	-0.007±0.86	-0.03±0.87	-0.07±0.82	0.23±0.96
Logic 2 (z-scores)	0.10±1.0	0.11±1.07	0.008±0.97	0.33±0.88
Logic 2 (delta change z-scores)	-0.012±0.75	0.042±0.8	-0.06±0.75	-0.04±0.67
Trails Making Test-A time (z-scores)	0.062±1.06	-0.14±0.88	-0.33±1.04	0.12±0.89
Trails Making Test-A time (delta change z-scores)	0.048±0.88	0.025±0.14	0.127±0.7	-.093±1.03
Trails Making Test-B time (z-scores)	-0.17±0.96	-0.14±0.89	-0.33±1.04	0.12±0.9
Trails Making Test-B time (delta change z-scores)	-0.034±0.72	-0.007±0.65	-0.002±0.63	-0.19±0.64
DSST (z-scores)	0.2±0.95	0.2±0.83	0.14±1.03	0.36±1.11

DSST(delta change z-scores)	0.07±0.44	0.1±0.44	-.003±.45	0.18±0.37

462 *Statistical significant difference between the groups. Lower scores represent worse cognitive function.

Table 3: AD Biomarker characteristics

	ALL (n=208)	Normal (n=97)	Mild OSA (n=76)	Moderate-Severe OSA (n=35)
CSF Aβ42 baseline (n=179) Mean ± SD	681.31 ±236.43	681.88 ± 243.18	690.61 ± 233.99	657.48 ± 224.79
CSF Aβ42 annual change (n=104) Median (Interquartile range)	29.40 (-9.53,71.06)	40.59 (4.23,80.80)	26.97 (-29.99,66.71)	-4.088 (-18.97,27.92)
CSF P-tau baseline (n=179) Median (Interquartile range)	41 (31,52)	42.50 (31.5,52.05)	43.55 (30,55)	40.97 (31.71,49)
CSF P-tau annual change (n=104) Mean ± SD	1.42 ± 3.93	1.35 ± 3.18	0.73 ± 4.27	3.43 ± 4.90
CSF T-tau baseline (n=179) Median (Interquartile range)	257.96 (202,360.91)	268.04 (217.65,362)	244.85 (198,382)	248.14 (174,343)
CSF T-tau annual change (n=104) Mean ± SD	8.24 ± 21.42	7.52 ± 18.86	5.85 ± 21.83	17.04 ± 27.53
AD_{PiB} PET baseline (n=86) Median (Interquartile range)	1.05 (1.02,1.11)	1.047 (1.02,1.09)	1.061 (1.00,1.11)	1.06 (1.01,1.14)
AD_{PiB} PET annual change (n=34) Median (Interquartile range)	0.0005 (-0.009,0.014)	-0.0020 (-0.0095,0.0078)	-0.0022 (-0.0126,0.0224)	0.014 (0.006,0.028)

463 *Statistical significant difference between the groups.

Dependent variable		R^2	ΔR^2	Independent variables	B	95% CI	p
Annual ΔCSF Aβ42	Model 1	-.008	.035	Age	-1.36	-3.67, .95	.24
				Sex	6.63	-27.72, 40.99	.70
				BMI	.88	-2.36, 4.12	.59
				ApoE4	-15.54	-50.69, 8.81	.36
	Model 1 +AHI4	.028	.046	AHI4	-13.35	-26.06, -.64	.04
	Model 1	-.008	.035	Age	-1.57	-3.86, .70	.17
				Sex	4.07	-30.36, 38.51	.81
				BMI	1.0	-2.27, 4.27	.54
				ApoE4	-17.89	-52.58, 16.79	.30
	Model 1 +AHIall	.027	.044	AHIall	-29.08	-57.08, -1.08	.04

464

Dependent variable		R^2	ΔR^2	Independent variables	B	95% CI	p
Annual Ln ΔPiB	Model 1	-.068	.062	Age	.001	-.001, .004	.28
				Sex	.001	-.036, .038	.96

				BMI	-.001	-.004, .002	.37
				ApoE4	.01	-.026, .046	.36
	Model 1 +AHI4	.134	.072	**AHI4**	.013	-.004, .03	.13
	Model 1	-.068	.062	**Age**	.001	-.001, .004	.25
				Sex	.001	-.036, .038	.96
				BMI	-.001	-.004, .002	.37
				ApoE4	.01	-.026, .046	.56
	Model 1 +AHIall	.151	.09	**AHIall**	.026	-005, .057	.09

Table 4: Final model showing relationship of annual ΔCSF Aβ42 and annual ln ΔPiB with AHIall and AHI4%.

Figures

Figure 1



Figure 2



Figure 3



Figure 4



Figure 5



Study flow chart showing a detailed breakdown of subjects based on AD biomarker evaluations at the baseline and follow up visits.

Reference List

1. Hebert, L. E., L. A. Beckett, P. A. Scherr, and D. A. Evans. 2001. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. *Alzheimer Dis.Assoc.Disord.* 15:169-173.

2. Heinzer, R., H. Marti-Soler, and J. Haba-Rubio. 2016. Prevalence of sleep apnoea syndrome in the middle to old age general population. *Lancet Respir.Med.* 4:e5-e6.

3. Yaffe, K., A. M. Laffan, S. L. Harrison, S. Redline, A. P. Spira, K. E. Ensrud, S. Ancoli-Israel, and K. L. Stone. 2011. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. *JAMA* 306:613-619.

4. Ayas, N. T., L. F. Drager, M. J. Morrell, and V. Y. Polotsky. 2017. Update in Sleep-disordered Breathing 2016. *Am.J.Respir.Crit Care Med.* 195:1561-1566.

5. Gozal, D. and L. Kheirandish-Gozal. 2008. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. *Am.J.Respir.Crit Care Med.* 177:369-375.

6. Shahar, E., C. W. Whitney, S. Redline, E. T. Lee, A. B. Newman, N. F. Javier, G. T. O'Connor, L. L. Boland, J. E. Schwartz, and J. M. Samet. 2001. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am.J.Respir.Crit Care Med.* 163:19-25.

7. Sanchez-de-la-Torre, M., F. Campos-Rodriguez, and F. Barbe. 2013. Obstructive sleep apnoea and cardiovascular disease. *Lancet Respir.Med.* 1:61-72.

8. Ancoli-Israel, S., E. R. DuHamel, C. Stepnowsky, R. Engler, M. Cohen-Zion, and M. Marler. 2003. The relationship between congestive heart failure, sleep apnea, and mortality in older men. *Chest* 124:1400-1405.

9. Mehra, R., K. L. Stone, P. D. Varosy, A. R. Hoffman, G. M. Marcus, T. Blackwell, O. A. Ibrahim, R. Salem, and S. Redline. 2009. Nocturnal Arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study. *Arch.Intern.Med.* 169:1147-1155.

10. Fung, M. M., K. Peters, S. Redline, M. G. Ziegler, S. Ancoli-Israel, E. Barrett-Connor, and K. L. Stone. 2011. Decreased slow wave sleep increases risk of developing hypertension in elderly men. *Hypertension* 58:596-603.

11. Osorio, R. S., T. Gumb, E. Pirraglia, A. W. Varga, S. E. Lu, J. Lim, M. E. Wohlleber, E. L. Ducca, V. Koushyk, L. Glodzik, et al. 2015. Sleep-disordered breathing advances cognitive decline in the elderly. *Neurol* 84:1964-1971.

12. Emamian, F., H. Khazaie, M. Tahmasian, G. D. Leschziner, M. J. Morrell, G. Y. Hsiung, I. Rosenzweig, and A. A. Sepehry. 2016. The Association Between Obstructive Sleep Apnea and Alzheimer's Disease: A Meta-Analysis Perspective. *Front Aging Neurosci.* 8:78.

13. Spira, A. P., C. Yager, J. Brandt, G. S. Smith, Y. Zhou, A. Mathur, A. Kumar, J. R. Brasic, D. F. Wong, and M. N. Wu. 2014. Objectively Measured Sleep and beta-amyloid Burden in Older Adults: A Pilot Study. *SAGE Open.Med.* 2.

14. Osorio, R. S., I. Ayappa, J. Mantua, T. Gumb, A. Varga, A. M. Mooney, O. E. Burschtin, Z. Taxin, E. During, N. Spector, et al. 2014. The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. *Neurobiology of Aging* 35:1318-1324.

15. Liguori, C., N. B. Mercuri, F. Izzi, A. Romigi, A. Cordella, G. Sancesario, and F. Placidi. 2017. Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes. *Sleep* 40.

16. Helzner, E. P., J. A. Luchsinger, N. Scarmeas, S. Cosentino, A. M. Brickman, M. M. Glymour, and Y. Stern. 2009. Contribution of vascular risk factors to the progression in Alzheimer disease. *Arch.Neurol.* 66:343-348.

17. De La Torre, J. C. 2008. Pathophysiology of neuronal energy crisis in Alzheimer's disease. *Neurodegener.Dis.* 5:126-132.

18. De Santi, S., E. Pirraglia, W. B. Barr, J. Babb, S. Williams, K. Rogers, L. Glodzik, M. Brys, L. Mosconi, B. Reisberg, et al. 2008. Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline. *Neuropsychology* 22:469-484.

19. Folstein, M. F., L. N. Robins, and J. E. Helzer. 1983. The Mini-Mental State Examination. *Arch.Gen.Psychiatry* 40:SP - 812.

20. Morris, J. C. 1993. The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurol* 43:2412-2414.

21. Johns, M. W. 1991. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 14:540-545.

22. Ayappa, I., R. G. Norman, V. Seelall, and D. M. Rapoport. 2008. Validation of a self-applied unattended monitor for sleep disordered breathing. *J.Clin.Sleep Med.* 4:26-37.

23. Tiihonen, P., T. Hukkanen, H. Tuomilehto, E. Mervaala, and J. Toyras. 2009. Evaluation of a novel ambulatory device for screening of sleep apnea. *Telemed.J.E.Health* 15:283-289.

24. Ayappa, I., R. G. Norman, M. Suryadevara, and D. M. Rapoport. 2004. Comparison of limited monitoring using a nasal-cannula flow signal to full polysomnography in sleep-disordered breathing. *Sleep* 27:1171-1179.

25. Spiegel, J., E. Pirraglia, R. S. Osorio, L. Glodzik, Y. Li, W. Tsui, L. A. Saint Louis, C. Randall, T. Butler, J. Xu, et al. 2015. Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. *Journal of Alzheimer's Disease* 49:93-100,2015.

26. Vanderstichele, H., M. Bibl, S. Engelborghs, B. N. Le, P. Lewczuk, J. L. Molinuevo, L. Parnetti, A. Perret-Liaudet, L. M. Shaw, C. Teunissen, et al. 2012. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers.Dement.* 8:65-73.

27. Mosconi, L., J. Rinne, W. Tsui, J. Murray, Y. Li, L. Glodzik, P. McHugh, S. Williams, M. Cummings, E. Pirraglia, et al. 2013. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. *Neurobiology of Aging* 34:22-34.

28. Price, J. C., W. E. Klunk, B. J. Lopresti, X. Lu, J. A. Hoge, S. K. Ziolko, D. P. Holt, C. C. Meltzer, S. T. DeKosky, and C. A. Mathis. 2005. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. *Journal of Cerebral Blood Flow & Metabolism* 25:1528-1547.

29. Jack, C. R. Jr., D. S. Knopman, W. J. Jagust, L. M. Shaw, P. S. Aisen, M. W. Weiner, R. C. Petersen, and J. Q. Trojanowski. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol.* 9:119-128.

30. Mielke, M. M., H. J. Wiste, S. D. Weigand, D. S. Knopman, V. J. Lowe, R. O. Roberts, Y. E. Geda, D. M. Swenson-Dravis, B. F. Boeve, M. L. Senjem, et al. 2012. Indicators of amyloid burden in a population-based study of cognitively normal elderly. *Neurol* 79:1570-1577.

31. Nordberg, A., S. F. Carter, J. Rinne, A. Drzezga, D. J. Brooks, R. Vandenberghe, D. Perani, A. Forsberg, B. Langstrom, N. Scheinin, et al. 2013. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. *Eur.J.Nucl.Med.Mol.Imaging* 40:104-114.

32. Villeneuve, S., G. D. Rabinovici, B. I. Cohn-Sheehy, C. Madison, N. Ayakta, P. M. Ghosh, R. La Joie, S. K. Arthur-Bentil, J. W. Vogel, S. M. Marks, et al. 2015. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. *Brain* 138:2020-2033.

33. Martin, M. S., E. Sforza, F. Roche, J. C. Barthelemy, C. Thomas-Anterion, and PROOF study group. 2015. Sleep breathing disorders and cognitive function in the elderly: an 8-year follow-up study. the proof-synapse cohort. *Sleep* 38:179-187.

34. Sforza, E., F. Roche, C. Thomas-Anterion, J. Kerleroux, O. Beauchet, S. Celle, D. Maudoux, V. Pichot, B. Laurent, and J. C. Barthelemy. 2010. Cognitive function and sleep related breathing disorders in a healthy elderly population: the SYNAPSE study. *Sleep* 33:515-521.

35. Palmqvist, S., H. Zetterberg, N. Mattsson, P. Johansson, L. Minthon, K. Blennow, M. Olsson, and O. Hansson. 2015. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. *Neurol* 85:1240-1249.

36. Maia, L. F., S. A. Kaeser, J. Reichwald, M. Lambert, U. Obermuller, J. Schelle, J. Odenthal, P. Martus, M. Staufenbiel, and M. Jucker. 2015. Increased CSF Abeta during the very early phase of cerebral Abeta deposition in mouse models. *EMBO Mol.Med.* 7:895-903.

37. Shoji, M., M. Kanai, E. Matsubara, Y. Tomidokoro, M. Shizuka, Y. Ikeda, M. Ikeda, Y. Harigaya, K. Okamoto, and S. Hirai. 2001. The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently. *Neurobiology of Aging*209-215.

38. Varga, A. W., M. E. Wohlleber, S. Gimenez, S. Romero, J. F. Alonso, E. L. Ducca, K. Kam, C. Lewis, E. B. Tanzi, S. Tweardy, et al. 2016. Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly. *Sleep* 39:2041-2048.

39. Ju, Y. E., S. J. Ooms, C. Sutphen, S. L. Macauley, M. A. Zangrilli, G. Jerome, A. M. Fagan, E. Mignot, J. M. Zempel, J. A. H. R. Claassen, et al. 2017. Slow wave sleep disruption increases cerebrospinal fluid amyloid-Î² levels. *Brain* 140:2104-2111.

40. Ju, Y. S., M. B. Finn, C. L. Sutphen, E. M. Herries, G. M. Jerome, J. H. Ladenson, D. L. Crimmins, A. M. Fagan, and D. M. Holtzman. 2016. Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid. *Ann.Neurol.*

41. Ooms, S., S. Overeem, K. Besse, M. O. Rikkert, M. Verbeek, and J. A. Claassen. 2014. Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid beta-Amyloid 42 in Healthy Middle-Aged Men: A Randomized Clinical Trial. *JAMA Neurol.*

42. Schwartz, A. R., H. Schneider, P. L. Smith, B. M. McGinley, S. P. Patil, and J. P. Kirkness. 2011. Physiologic phenotypes of sleep apnea pathogenesis. *Am.J.Respir.Crit Care Med.* 184:1105-1106.

43. Ratnavadivel, R., D. Stadler, S. Windler, J. Bradley, D. Paul, R. D. McEvoy, and P. G. Catcheside. 2010. Upper airway function and arousability to ventilatory challenge in slow wave versus stage 2 sleep in obstructive sleep apnoea. *Thorax* 65:107-112.

44. Saboisky, J., D. Eckert, and A. Malhotra. 2010. Stable breathing through deeper sleeping. *Thorax* 65:95-96.

45. Wellman, A., A. S. Jordan, A. Malhotra, R. B. Fogel, E. S. Katz, K. Schory, J. K. Edwards, and D. P. White. 2004. Ventilatory control and airway anatomy in obstructive sleep apnea. *Am.J.Respir.Crit Care Med.* 170:1225-1232.

46. Ondze, B., F. Espa, Y. Dauvilliers, M. Billiard, and A. Besset. 2003. Sleep architecture, slow wave activity and sleep spindles in mild sleep disordered breathing. *Clin.Neurophysiol.* 114:867-874.

47. Brillante, R., G. Cossa, P. Y. Liu, and L. Laks. 2012. Rapid eye movement and slow-wave sleep rebound after one night of continuous positive airway pressure for obstructive sleep apnoea. *Respirology.* 17:547-553.

48. Pase, M. P., J. J. Himali, N. A. Grima, A. S. Beiser, C. L. Satizabal, H. J. Aparicio, R. J. Thomas, D. J. Gottlieb, S. H. Auerbach, and S. Seshadri. 2017. Sleep architecture and the risk of incident dementia in the community. *Neurol*.

49. Lim, A. S., M. Kowgier, L. Yu, A. S. Buchman, and D. A. Bennett. 2013. Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. *Sleep* 36:1027-1032.

50. Baril, A. A., K. Gagnon, P. Brayet, J. Montplaisir, B. L. De, J. Carrier, C. Lafond, F. L'Heureux, J. F. Gagnon, and N. Gosselin. 2017. Gray Matter Hypertrophy and Thickening with Obstructive Sleep Apnea in Middle-aged and Older Adults. *Am.J.Respir.Crit Care Med.* (In press)

51. O'Donoghue, F. J., R. S. Briellmann, P. D. Rochford, D. F. Abbott, G. S. Pell, C. H. Chan, N. Tarquinio, G. D. Jackson, and R. J. Pierce. 2005. Cerebral structural changes in severe obstructive sleep apnea. *Am.J.Respir.Crit Care Med.* 171:1185-1190.

52. Shiota, S., H. Takekawa, S. E. Matsumoto, K. Takeda, F. Nurwidya, Y. Yoshioka, F. Takahashi, N. Hattori, T. Tabira, H. Mochizuki, et al. 2013. Chronic intermittent hypoxia/reoxygenation facilitate amyloid-beta generation in mice. *J.Alzheimers.Dis.* 37:325-333.

53. Tabuchi, M., S. R. Lone, S. Liu, Q. Liu, J. Zhang, A. P. Spira, and M. N. Wu. 2015. Sleep interacts with abeta to modulate intrinsic neuronal excitability. *Curr.Biol.* 25:702-712.

54. Lavie, P., L. Lavie, and P. Herer. 2005. All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age. *Eur.Respir.J.* 25:514-520.